Stanley-Laman Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.34M | Buy |
42,521
+9,862
| +30% | +$1.24M | 0.79% | 34 |
|
|
2025
Q1 | $3.61M | Sell |
32,659
-9,499
| -23% | -$1.05M | 0.56% | 77 |
|
|
2024
Q4 | $5.75M | Buy |
42,158
+4,627
| +12% | +$632K | 0.81% | 26 |
|
|
2024
Q3 | $4.32M | Buy |
37,531
+10,088
| +37% | +$1.16M | 0.61% | 63 |
|
|
2024
Q2 | $3.78M | Buy |
+27,443
| New | +$3.78M | 0.54% | 82 |
|
|
2018
Q3 | – | Sell |
-89,884
| Closed | -$8.83M | – | 233 |
|
|
2018
Q2 | $8.83M | Buy |
89,884
+10,728
| +14% | +$1.05M | 1.98% | 3 |
|
|
2018
Q1 | $6.56M | Sell |
79,156
-9,990
| -11% | -$828K | 1.5% | 7 |
|
|
2017
Q4 | $6.92M | Buy |
89,146
+33,723
| +61% | +$2.62M | 1.49% | 6 |
|
|
2017
Q3 | $3.4M | Buy |
+55,423
| New | +$3.4M | 0.91% | 36 |
|